Therapeutic application of melatonin in mild cognitive impairment

American Journal of Neurodegenerative Diseases

Volumn 1, Issue 3, 2012, Pages 280-291

  Cardinali, Daniel P ^a   Vigo, Daniel E ^a   Olivar, Natividad ^b   Vidal, María F ^a   Furio, Analía M ^b   Brusco, Luis I ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Alzheimer s disease; Benzodiazepines; Melatonin; Mild cognitive impairment; Neuropsychological tests; Retrospective study

Indexed keywords

ALPRAZOLAM; ATENOLOL; BENZODIAZEPINE; CLONAZEPAM; DONEPEZIL; ESCITALOPRAM; LEVOMEPROMAZINE; LEVOTHYROXINE; LORAZEPAM; MELATONIN; NOOTROPIC AGENT; NORSERTRALINE; PAROXETINE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; RETROSPECTIVE STUDY; SLEEP QUALITY; WAKEFULNESS;

EID: 84980053539     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Singh-Manoux A, Kivimaki M, Glymour MM, Elbaz A, Berr C, Ebmeier KP, Ferrie JE, and Dugravot A. Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ 2012; 344: d7622.
2. Silveri MC, Reali G, Jenner C, and Puopolo M. Attention and memory in the preclinical stage of dementia. J Geriatr Psychiatry Neurol 2007; 20: 67-75.
3. Weaver CJ, Maruff P, Collie A, and Masters C. Mild memory impairment in healthy older adults is distinct from normal aging. Brain Cogn 2006; 60: 146-155.
4. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, and Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004; 61: 59-66.
5. Dubois B and Albert ML. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol 2004; 3: 246-248.
6. Farias ST, Mungas D, Reed BR, Harvey D, and DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009; 66: 1151-1157.
7. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, and Masters CL. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988; 38: 1688-1693.
8. Price JL and Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358- 368.
9. Braak H and Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-278.
10. Braak H and Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998; 53: 127-140.
11. Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, and Cardinali DP. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neuroto Res 2012, in press.
12. Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, Van Kan HJ, Fischer DF, Ravid R, and Swaab DF. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88: 5898-5906.
13. Zhou JN, Liu RY, Kamphorst W, Hofman MA, and Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35: 125- 130.
14. Furio AM, Brusco LI, and Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment. A retrospective study. J Pineal Res 2007; 43: 404-409.
15. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
16. Fainstein I, Bonetto A, Brusco LI, and Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res 1997; 58: 990-1000.
17. Jean-Louis G, von Gizycki H, and Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998; 25: 177-183.
18. Mishima K, Okawa M, Hozumi S, and Hishikawa Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 2000; 17: 419-432.
19. Cohen-Mansfield J, Garfinkel D, and Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study. Arch Gerontol Geriatr 2000; 31: 65-76.
20. Mahlberg R, Kunz D, Sutej I, Kuhl KP, and Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004; 24: 456- 459.
21. Brusco LI, Marquez M, and Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuro Endocrinol Lett 1998; 19: 111-115.
22. Cardinali DP, Brusco LI, Liberczuk C, and Furio AM. The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 2002; 23 Suppl 1: 20-23.
23. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, and Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003; 70: 334-341.
24. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, and Thal LJ. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 893-901.
25. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, and Reiter RJ. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000; 107: 203-231.
26. Cardinali DP, Furio AM, and Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol 2010; 8: 218-227.
27. de Jonghe A, Korevaar JC, van Munster BC, and de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry 2010; 25: 1201-1208.
28. 2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005; 38: 10-16.
29. Wu YH and Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007; 8: 623-636.
30. Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J, and Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 2005; 1037: 209-213.
31. Cardinali DP, Furio AM, and Brusco LI. The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease. Recent Pat Endocr Metab Immune Drug Discov 2011; 5: 80-90.
32. Jean-Louis G, Zizi F, von Gizycki H, and Taub H. Effects of melatonin in two individuals with Alzheimer's disease. Percept Mot Skills 1998; 87: 331-339.
33. Peck JS, LeGoff DB, Ahmed I, and Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry 2004; 12: 432-436.
34. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, and van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008; 299: 2642-2655.
35. Thome J, Coogan AN, Woods AG, Darie CC, and Hassler F. CLOCK Genes and Circadian Rhythmicity in Alzheimer Disease. J Aging Res 2011; 2011: 383091
36. Zhong G, Naismith SL, Rogers NL, and Lewis SJ. Sleep-wake disturbances in common neurodegenerative diseases: a closer look at selected aspects of the neural circuitry. J Neurol Sci 2011; 307: 9-14.
37. Bachman D and Rabins P. "Sundowning" and other temporally associated agitation states in dementia patients. Annu Rev Med 2006; 57: 499-511.
38. Oosterman JM, van Someren EJ, Vogels RL, Van Harten B, and Scherder EJ. Fragmentation of the rest-activity rhythm correlates with agerelated cognitive deficits. J Sleep Res 2009; 18: 129-135.
39. Rosales-Corral SA, Acuna-Castroviejo D, Coto-Montes A, Boga JA, Manchester LC, Fuentes-Broto L, Korkmaz A, Ma S, Tan DX, and Reiter RJ. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res 2012; 52: 167-202.
40. Beaulieu-Bonneau S and Hudon C. Sleep disturbances in older adults with mild cognitive impairment. Int Psychogeriatr 2009; 21: 654- 666.
41. Geda YE, Smith GE, Knopman DS, Boeve BF, Tangalos EG, Ivnik RJ, Mrazek DA, Edland SD, and Petersen RC. De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr 2004; 16: 51-60.
42. Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, Ensrud KE, Cauley JA, Redline S, Hillier TA, Cummings SR, and Yaffe K. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol 2011; 70: 722-732.
43. Cochrane A, Robertson IH, and Coogan AN. Association between circadian rhythms, sleep and cognitive impairment in healthy older adults: an actigraphic study. J Neural Transm 2012, in press.
44. Vollrath L, Semm P, and Gammel G. Sleep induction by intranasal administration of melatonin. Adv Biosci 1981; 29: 327-329.
45. Waldhauser F, Saletu B, and Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl) 1990; 100: 222-226.
46. Cardinali DP, Srinivasan V, Brzezinski A, and Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012; 52: 365-375.
47. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, and Baker G. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332: 385-393.
48. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben Shushan A, and Ford I. Effects of exogenous melatonin on sleep: a metaanalysis. Sleep Med Rev 2005; 9: 41-50.
49. Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, and Wade AG. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24: 1577-1601.
50. Cardinali DP, Pandi-Perumal SR and Niles LP Melatonin and Its Receptors: Biological Function in Circadian Sleep-Wake Regulation. In: Monti JM, Pandi-Perumal SR, Sinton CM, editors. Neurochemistry of Sleep and Wakefulness, Cambridge UK: Cambridge University Press, 2008; pp: 283-314.
51. Detanico BC, Piato AL, Freitas JJ, Lhullier FL, Hidalgo MP, Caumo W, and Elisabetsky E. Antidepressant- like effects of melatonin in the mouse chronic mild stress model. Eur J Pharmacol 2009; 607: 121-125.
52. McElroy SL, Winstanley EL, Martens B, Patel NC, Mori N, Moeller D, McCoy J, and Keck PE Jr. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2010; 26: 48- 53.
53. Crupi R, Mazzon E, Marino A, La Spada G, Bramanti P, Cuzzocrea S, and Spina E. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J Pineal Res 2010; 49: 123-129.
54. Monti JM, Alvarino F, Cardinali DP, Savio I, and Pintos A. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatrics 1999; 28: 85-98.
55. Furio AM, Cutrera RA, Castillo T, V, Perez LS, Riccio P, Caccuri RL, Brusco LL, and Cardinali DP. Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. Cell Mol Neurobiol 2002; 22: 699-709.
56. Cardinali DP, Cano P, Jimenez-Ortega V, and Esquifino AI. Melatonin and the metabolic syndrome. Physiopathologic and therapeutical implications. Neuroendocrinology 2011; 93: 133-142.
57. Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, and Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009; 373: 482-491.
58. Mulchahey JJ, Goldwater DR, and Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6- chloromelatonin. Life Sci 2004; 75: 1843- 1856.
59. Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G, Schneider A, Bach A, Siren AL, Hardeland R, Bahr M, Nave KA, and Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-323.
60. Chahbouni M, Escames G, Venegas C, Sevilla B, Garcia JA, Lopez LC, Munoz-Hoyos A, Molina-Carballo A, and Acuna-Castroviejo D. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-289.
61. Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, and Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39: 307-313.
62. Voordouw BC, Euser R, Verdonk RE, Alberda BT, de Jong FH, Drogendijk AC, Fauser BC, and Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992; 74: 108-117.
63. Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, Pelzll H, Gotthardt DN, Cekauskas A, Manikas M, Mikalauskas S, Mikalauskene L, Bruns H, Zorn M, Weigand MA, Buchler MW, and Schemmer P. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res 2011; 50: 381-388.
64. Golombek DA, Pevet P, and Cardinali DP. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev 1996; 20: 403-412.
65. Dagan Y, Zisapel N, Nof D, Laudon M, and Atsmon J. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol 1997; 7: 157-160.
66. Garfinkel D, Zisapel N, Wainstein J, and Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 1999; 159: 2456-2460.
67. Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI, and Cardinali DP. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleepdisturbed, middle-aged, and elderly patients. J Pineal Res 2001; 30: 34-42.
68. Kunz D, Bineau S, Maman K, Milea D, and Toumi M. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother 2012; 13: 9-16.
69. Fetveit A. Late-life insomnia: a review. Geriatr Gerontol Int 2009; 9: 220-234.
70. Morin CM and Benca R. Chronic insomnia. Lancet 2012; 379: 1129-1141.
71. Boyle N, Naganathan V, and Cumming RG. Medication and falls: risk and optimization. Clin Geriatr Med 2010; 26: 583-605.
72. Faught E. Monotherapy in adults and elderly persons. Neurology 2007; 69: S3-S9.